Advanced Biomed Inc. Files S-1/A Amendment

Ticker: ADVB · Form: S-1/A · Filed: Jan 27, 2025 · CIK: 1941029

Advanced Biomed INC. S-1/A Filing Summary
FieldDetail
CompanyAdvanced Biomed INC. (ADVB)
Form TypeS-1/A
Filed DateJan 27, 2025
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.001, $4.00, $6.00
Sentimentneutral

Sentiment: neutral

Topics: ipo, registration, sec-filing

TL;DR

Advanced Biomed Inc. filed an S-1/A, looks like they're still prepping for an IPO.

AI Summary

Advanced Biomed Inc. filed an S-1/A amendment on January 27, 2025, for its registration statement. The company, incorporated in Nevada, has its principal executive offices at 689-85 Xiaodong Road, Yongkang District, Tainan City, Taiwan, with a phone number of 886-6-3121716. Cogency Global Inc. is listed as the agent for service at 122 East 42nd Street, New York, NY 10168.

Why It Matters

This S-1/A filing indicates Advanced Biomed Inc. is moving forward with its public offering registration, which could lead to new investment opportunities and increased market visibility for the company.

Risk Assessment

Risk Level: medium — S-1/A filings are part of the IPO process, which inherently carries risks related to market reception and company execution.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this S-1/A filing?

This is an amendment to a previously filed S-1 registration statement, indicating ongoing efforts to register securities for a public offering.

Where are Advanced Biomed Inc.'s principal executive offices located?

The principal executive offices are located at 689-85 Xiaodong Road, Yongkang District, Tainan City, Taiwan.

Who is the agent for service for Advanced Biomed Inc.?

Cogency Global Inc., located at 122 East 42nd Street, 18th Floor, New York, NY 10168, is the agent for service.

When was this amendment filed?

This amendment was filed with the SEC on January 27, 2025.

What is the company's state of incorporation?

Advanced Biomed Inc. is incorporated in Nevada.

Filing Stats: 4,535 words · 18 min read · ~15 pages · Grade level 18.2 · Accepted 2025-01-27 13:53:45

Key Financial Figures

Filing Documents

From the Filing

As filed with the United States Securities and Exchange Commission on January 27, 2025. Registration No. 333-272110 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 15 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Advanced Biomed Inc. (Exact name of registrant as specified in its charter) Nevada 8071 87-2177170 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) No. 689-85 Xiaodong Road, Yongkang District Tainan City, Taiwan Tel: 886-6-3121716 (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices) Cogency Global Inc. 122 East 42nd Street, 18th Floor New York, NY 10168 (212) 947-7200 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies of all communications to: Fang Liu, Esq. VCL Law LLP William S. Rosenstadt, Esq. Mengyi “Jason” Ye, Esq. 1945 Old Gallows Road Ortoli Rosenstadt LLP Suite 260 366 Madison Avenue, 3rd Floor Vienna, VA 22182 New York, NY 10017 Telephone: (703) 919-7285 Telephone: (212) 588-0022 Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement. If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box: If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. Large Accelerated Filer Accelerated Filer Non-Accelerated Filer Smaller Reporting Company Emerging Growth Company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall hereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the United States Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine. EXPLANATORY NOTE This Registration Statement contains two prospectuses, as set forth below. Primary Offering Prospectus. A prospectus to be used for the initial primary underwritten public offering of 1,875,000 Common Stock of the Registrant through the underwriter named on the cover page of the Primary Offering Prospectus. The initial primary underwritten public offering is referred to as the “Primary Offering.” Resale Prospectus. A prospectus to be used for the resale by the selling stockholders of up to 1,875,000 Common Stock of the Registrant (the “Resale Shares” and each a “Resale Share”). Each of the two selling stockholders identified in the Resale Prospectus is referred to as a “Selling Stockholder” and together, “Selling Stockholders.” The offering of the Resale Shares is referred to as the “Resale Offering.” The Resale Prospectus is substantively identical to the Primary Offering Prospectus, except for the following principal points: they contain different outside and inside front covers and back covers; the Offering section in the Prospectus Summary section from the Primary Offering Prospectus on page 12 is deleted and replaced with a revised the Offering section on page Alt-1; the Use of Proceeds section from the Primary Offering Prospectus on page 47 is deleted and replaced with a revised the Use of Proceeds sect

View Full Filing

View this S-1/A filing on SEC EDGAR

View on Read The Filing